泌尿外科慢性盆腔疼痛综合征中疼痛与泌尿症状的临床重要差异:MAPP网络研究
该研究基于MAPP症状模式研究,纳入泌尿外科慢性盆腔疼痛综合征患者,通过回归和ROC曲线将3至6个月内疼痛和泌尿症状变化与全局应答评估的明显改善关联,确定临床重要差异。结果显示盆腔疼痛严重程度绝对变化-4为临床重要,百分比变化30%至57%;女性泌尿症状绝对变化-3,仅慢性前列腺炎/慢性盆腔疼痛综合征男性为-2。结论认为盆腔疼痛严重程度降低30%至50%是未来治疗试验的临床有意义终点,泌尿症状临床重要差异宜按性别分别定义。
要点
- 盆腔疼痛严重程度绝对变化-4在所有患者中为临床重要差异。
- 盆腔疼痛严重程度百分比变化的临床重要差异在各亚组间更一致,范围为30%至57%。
- 泌尿症状严重程度绝对变化临床重要差异女性为-3,仅慢性前列腺炎/慢性盆腔疼痛综合征男性为-2。
核心结论
- 盆腔疼痛严重程度降低30%至50%是未来泌尿外科慢性盆腔疼痛综合征治疗试验的临床有意义终点。
- 泌尿症状严重程度临床重要差异更宜按男性和女性参与者分别定义。
研究设计与样本
- 多学科慢性盆腔疼痛研究方法症状模式研究纳入泌尿外科慢性盆腔疼痛综合征个体。
- 通过回归和受试者工作特征曲线将3至6个月内盆腔疼痛严重程度和泌尿症状严重程度变化与全局应答评估的明显改善关联以定义临床重要差异。
- 评估绝对变化和百分比变化的临床重要差异,并按性别-诊断、Hunner病变存在、疼痛类型、疼痛广泛性和基线症状严重程度检查差异。
主要发现
- 盆腔疼痛严重程度绝对变化-4在所有患者中为临床重要,但临床重要差异估计因疼痛类型、Hunner病变存在和基线严重程度而异。
- 盆腔疼痛严重程度百分比变化的临床重要差异估计在各亚组间更一致,范围为30%至57%。
- 泌尿症状严重程度绝对变化临床重要差异女性参与者为-3,仅慢性前列腺炎/慢性盆腔疼痛综合征男性参与者为-2。
- 基线严重程度更高的患者需要更大的症状减轻才能感到改善。
- 在基线症状低的参与者中,估计的临床重要差异准确性较低。
关键数值与推荐
- 盆腔疼痛严重程度绝对变化-4为所有患者的临床重要差异。
- 盆腔疼痛严重程度百分比变化临床重要差异范围为30%至57%。
- 泌尿症状严重程度绝对变化临床重要差异女性为-3,仅慢性前列腺炎/慢性盆腔疼痛综合征男性为-2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Symptom heterogeneity in interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome, collectively termed urological chronic pelvic pain syndrome, has resulted in difficulty in defining appropriate clinical trial endpoints. We determine clinically important differences for 2 primary symptom measures, pelvic pain severity and urinary symptom severity, and evaluate subgroup differences. MATERIALS AND METHODS: The Multidisciplinary Approach to the Study of Chronic Pelvic Pain Symptom Patterns Study enrolled individuals with urological chronic pelvic pain syndrome. We defined clinically important differences by associating changes in pelvic pain severity and urinary symptom severity over 3 to 6 months with marked improvement on a global response assessment using regression and receiver operating characteristic curves. We evaluated clinically important differences for absolute and percent change and examined differences in clinically important differences by sex-diagnosis, presence of Hunner lesions, pain type, pain widespreadness, and baseline symptom severity. RESULTS: An absolute change of -4 was clinically important in pelvic pain severity among all patients, but clinically important difference estimates differed by pain type, presence of Hunner lesions, and baseline severity. Pelvic pain severity clinically important difference estimates for percent change were more consistent across subgroups and ranged from 30% to 57%. The absolute change urinary symptom severity clinically important difference was -3 for female participants and -2 for male participants with chronic prostatitis/chronic pelvic pain syndrome only. Patients with greater baseline severity required larger decreases in symptoms to feel improved. Estimated clinically important differences had lower accuracy among participants with low baseline symptoms. CONCLUSIONS: A reduction of 30%-50% in pelvic pain severity is a clinically meaningful endpoint for future therapeutic trials in urological chronic pelvic pain syndrome. Urinary symptom severity clinically important differences are more appropriately defined separately for male and female participants.
引用
- Stephens-Shields AJ, Lai HH, Landis JR, et al. Clinically Important Differences for Pain and Urinary Symptoms in Urological Chronic Pelvic Pain Syndrome: A MAPP Network Study. J Urol. 2023. PMID: 36848118. doi:10.1097/JU.0000000000003394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。